

ondine



**For Immediate Release**

## **Ondine Announces FDA Confirmation of Regulatory Pathway for Periowave™**

**Vancouver, Canada – August 27, 2008** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced it has received confirmation from the U.S. Food & Drug Administration (FDA) that the Company's Periowave™ Photodisinfection System will be evaluated as a Class III medical device under premarket approval (PMA) regulations. Having received clarification of the regulatory pathway, the company intends to submit its existing clinical trial data as part of its PMA application to the FDA.

"The confirmation of the medical device regulatory pathway from the FDA is a significant milestone toward obtaining approval to market Periowave in the U.S.," said Carolyn Cross, President and CEO of Ondine Biopharma Corporation. "As stated in our December 20, 2007 press release, this regulatory designation recognizes the novel nature of the Periowave™ Photodynamic Disinfection system. With more than 20,000 patients treated in Canada and the EU, we are very pleased with the enthusiastic response from the clinical community in these markets and the increasing acceptance of this anti-bacterial technology. Once approved, we expect that the PMA will provide competitive barriers that will offer strategic benefits to Ondine in both the dental and medical markets."

### **About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com).

### **Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.*

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

**FOR FURTHER INFORMATION please contact:**

Carolyn Cross  
President and  
Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
ccross@ondinebiopharma.com

Adam Peeler  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 225  
apeeler@equicomgroup.com

Canaccord Adams Ltd  
Nominated Adviser &  
Broker  
Neil Johnson /  
Ryan Gaffney  
+4420 7050 6500